NewsBenzingaPasithea Therapeutics、PAS-004阻害薬の第I相用量漸増試験を発表;用量制限毒性は認められず;参加者のPAS-004中止なし;グレード3以上の有害事象なし Pasithea Therapeutics、PAS-004阻害薬の第I相用量漸増試験を発表;用量制限毒性は認められず;参加者のPAS-004中止なし;グレード3以上の有害事象なし Benzinga 2026.10.23 13:20 (GMT+0) Open on Benzinga Other news Airbnb Co-Founder Joe Gebbia Says He Modernized Federal Retirement System In 6 Months for $1.5 Million After Contractors Spent $100 Million NVIDIA's Jensen Huang Crisis Threatens to Rewrite the Rules of the AI Boom Mondelez's Multi-Million Portfolio Shift: Unloads French Bakery and Cereal Bars Business Ur-Energy Begins Fieldwork For Baseline Studies At Its Lost Solider Project; Will Take Construction Decision For Potential Third Mine After Technical Report Alibaba Is Facing a Perfect Storm, and Q2 Earnings Won’t Be a Magical Fix for BABA Stock CME Stock: Is Wall Street Bullish or Bearish?
Airbnb Co-Founder Joe Gebbia Says He Modernized Federal Retirement System In 6 Months for $1.5 Million After Contractors Spent $100 Million
Ur-Energy Begins Fieldwork For Baseline Studies At Its Lost Solider Project; Will Take Construction Decision For Potential Third Mine After Technical Report